Medsafe has opened a consultation on proposals to reduce barriers to accessing clozapine, a medicine used to treat treatment-resistant schizophrenia.

A formal regulatory inspection of Canterbury-based mental health services has set out a series of recommended changes for Health New Zealand and is continuing checks over the next 12 months.

In addition to the briefings published below, we also publish additional information alongside Cabinet material, including briefings to Ministers. These can be found at Information releases.Some parts ...

Residential disability services must notify the Ministry of Health before undertaking any of the following changes: changing patient or client capacity transferring existing clinical services ...

This framework contains information for health professionals and the public on the standards they should expect for evidence-based assessment, diagnosis, and treatment for ADHD in New Zealand.

The Registrar (assisted dying) Annual Report to the Minister of Health covers the period from 1 April 2024 to 31 March 2025.

The Director for Radiation Safety has reviewed the Code of Practice for Sealed Radioactive Material: ORS C12 2020. The review was conducted in accordance with section 90 of the Radiation Safety Act ...

This publication summarises funding to Māori health providers by the Ministry of Health, Health NZ and the now disestablished Māori Health Authority. It follows on from our previous reports in 2017, ...

Medsafe has given a New Zealand psychiatrist approval to prescribe medicinal psilocybin for treating treatment-resistant depression.

The plan sets out new key actions health entities and other government agencies will undertake from 2025 to 2029 to prevent suicide in New Zealand. The new actions are focused on addressing gaps and ...

This Regulatory Impact Statement was prepared by the Health Assurance Unit within the Public Service Commission in May 2025 to inform Cabinet decisions on amendments to the Pae Ora (Healthy Futures) ...